
Dechra will acquire Gallant Pet, Inc., a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell therapies for pets. This complementary transaction is aligned with Dechra’s long-term strategy to serve unmet needs in specialty care.
Dechra shares our commitment to innovation and addressing unmet needs in veterinary medicine. I couldn’t be more pleased about what this could mean for our future.” – Linda Black, DVM, PhD, CEO, at Gallant
Source: Dechra, November 9, 2026. Link. Completion of the transaction remains subject to customary closing conditions. The parties have agreed that the terms of the transaction will remain confidential.
Leave a Reply